Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Media Resources
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Search
  • Twitter

Press Releases

  • Home
  • News
  • Press Releases
News

Navigate News

  • Overview
  • Press Releases
  • Events
  • Presentations
  • In the News
  • Media Resources

Press Releases

  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

April 11, 2025

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

November 27, 2024

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

August 19, 2024

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

January 25, 2024

Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

December 28, 2023

Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

October 16, 2023

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

September 18, 2023

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

July 27, 2023

Titan Pharmaceuticals Provides Shareholder Update

December 15, 2022

UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

December 12, 2022

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...25
  • Next »
© 2025 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap Twitter